Atlas Trials

Escalation of Doses of Daratumumab in Combination With Chemotherapy (Idarubicin and Cytarabine or CPX-351) in Patients of 60 Years Old or More With Adverse Risk Acute Myeloblastic Leukemia (AML) (DARALAM)

Clinical trial NCT05749276 · RECRUITING

Trial details

NCT number
NCT05749276
Sponsor
Nantes University Hospital
Status
RECRUITING
Phase
Phase 1
Study type
INTERVENTIONAL
Adult Patients With Adverse Risk Acute Myeloblastic Leukemia
Start date
2025-02-06
Primary completion
2028-08-06
Enrollment
12

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.